Understanding Regs Key As CFDA Toughens GMP Enforcement
This article was originally published in PharmAsia News
Executive Summary
The China FDA is substantially beefing up inspections of foreign drug manufacturing sites, showing assertiveness and confidence towards China's own GMP standards after a massive domestic campaign to root out quality violators. For companies eyeing the world's second largest pharma market, staying out of trouble will require keeping on top of local regulatory updates, says an industry insider.
You may also be interested in...
2016 Review: Rapid Change Defines China Regulatory Environment
If you missed some of the many significant events in China’s policy and regulatory landscape in 2016, here is your opportunity to catch up on month-by-month developments.
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues.
Medtechs Must Reflect On China Localization Policies As VBP Expands
China continues to roll out volume-based procurement for medical devices and pharma products and companies should plan their strategies accordingly, advises EY Parthenon’s Hua Su.